TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04251962
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural solution containing fentanyl 3 mcg/ml (in addition to bupivacaine) in normal saline
Study: NCT01913158
Drug: Anucort-HC, 25 Mg Rectal Suppository
Normalized name: Anucort-HC, 25 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone acetate suppositories
Study: NCT00944658
Drug: Placebo (sugar pill)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day
Study: NCT01785849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (IV) three times per week.
Study: NCT00004036
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01439399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group (C) received an equal volume of saline 0.9 % during 48 h.
Study: NCT01633359
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
Study: NCT02561741
Drug: COV155
Approvals — FDA: no, EMA: no, PMDA: no
Description: COV155 tablets
Study: NCT04214093
Drug: AZD0466
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort.
Study: NCT01698567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
Study: NCT02233075
Drug: REP 2139-Ca + Pegasys (TM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
Study: NCT00965471
Drug: cipher prescription 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
Study: NCT03871959
Drug: DEBIO1143
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
Study: NCT02722161
Drug: [14C]BI 1482694
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00881907
Drug: Triple Antibiotic Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
Study: NCT02709265
Drug: amikacin/fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: single aerosolized dose
Study: NCT01581333
Drug: Empirical antimicrobial treatment discontinuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
Study: NCT01581333
Drug: Standard empirical antimicrobial treatment discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3.
Study: NCT03583905
Drug: Placebo of CKD-330
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of CKD-330 Tab.
Study: NCT03583905
Drug: D086
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D086 Tab.
Study: NCT03583905
Drug: Placebo of D086
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of D086 Tab.
Study: NCT03583905
Drug: Placebo of D723
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of D723 Tab.
Study: NCT00957905
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00957905
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03684772
Drug: ICVT Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin and Furosemide (0.125%)
Study: NCT02847338
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
Study: NCT03161509
Drug: Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
Study: NCT00553852
Drug: Recombinant GH Saizen (Merck-Serono)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
Study: NCT02315872
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections twice weekly for 28 weeks.
Study: NCT00600405
Drug: Standard therapy with ibuprofen and oxycodone.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
Study: NCT02642640
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005867
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005867
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005867
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01718223
Drug: photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo interstitial photodynamic therapy using temoporfin
Study: NCT02125409
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of Adiro 100 mg will be administered daily for 7 days.
Study: NCT02988232
Drug: Sogyeonghwalhyeol-tang
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: herbal extract
Study: NCT02988232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: extract powder with same appearance, odor and color as SGHH
Study: NCT00430586
Drug: Botulinum neurotoxin type A, free of complexing proteins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
Study: NCT00430586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
Study: NCT02598011
Drug: Toca FC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side
Study: NCT00335959
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
Study: NCT02539134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-935 placebo-matching oral solution
Study: NCT06037577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT00862459
Drug: OptiMARK~0.1 mmol/kg BW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
Study: NCT01921738
Drug: 1% Azithromycin gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
Study: NCT01921738
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
Study: NCT01921738
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
Study: NCT01921738
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
Study: NCT00774826
Drug: R-CVP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
Study: NCT00774826
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
Study: NCT00774826
Drug: R-FM
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
Study: NCT00540800
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: for metastatic breast cancer patients previously treated with anthracyclines
Study: NCT00674609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
Study: NCT00674609
Drug: THC Alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
Study: NCT03870776
Drug: MAP4343
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral administration of MAP4343
Study: NCT03870776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral administration of Placebo
Study: NCT00560586
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 puff each nostril at bedtime
Study: NCT00164021
Drug: Anti-reflux pharmacotherapy
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04392648
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide tablets orally.
Study: NCT00816816
Drug: docetaxel, cisplatin, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly.
Study: NCT00132080
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
Study: NCT02607176
Drug: Heweizhixie capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 #, Tid, Oral for 3 days
Study: NCT02169089
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
Study: NCT02169089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00476151
Drug: placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive placebo cream applied two times daily
Study: NCT03406299
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 30 mg/b.i.d., day 1-7
Study: NCT02748694
Drug: TAK-041 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-041 placebo-matching suspension or tablet.
Study: NCT02475317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.
Study: NCT01109979
Drug: Estradiol+MPA
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
Study: NCT01109979
Drug: Estradiol+Drospirenone
Normalized name: drospirenone / estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
Study: NCT00605137
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00201825
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
Study: NCT00361101
Drug: AMD11070
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg PO BID (by mouth two times per day) for 10 days.
Study: NCT04175301
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet also contains 80 mg magnesium
Study: NCT03129009
Drug: Total intravenous anesthesia group
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
Study: NCT03129009
Drug: Balanced anesthesia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
Study: NCT03155932
Drug: APD334
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD334 active treatment for 24 weeks.
Study: NCT03097861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mcg administered orally BID
Study: NCT03345407
Drug: Standard of care therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
Study: NCT00689416
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg, tablet, once daily for 3 months.
Study: NCT00689416
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg, tablet, once daily for 3 months
Study: NCT00576550
Drug: Urea
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea cream applied twice daily up to six months
Study: NCT03693989
Drug: Prednefrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~- Route of administration: topical ophthalmic
Study: NCT01799603
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
Study: NCT01017159
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
Study: NCT01381445
Drug: GW870086 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to slightly coloured opaque cream
Study: NCT01381445
Drug: GW870086 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to slightly coloured opaque cream
Study: NCT01381445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to slightly coloured opaque cream
Study: NCT00801606
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc 20 mg/day
Study: NCT00801606
Drug: Micronutrient without zinc
Normalized name: zinc bandage without supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimineral 2 RDA
Study: NCT00801606
Drug: Micronutrient with zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimineral 2 RDA and zinc 20 mg per day
Study: NCT00801606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01984099
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
Study: NCT00289952
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per standard of care.
Study: NCT03883984
Drug: Cysteamine Bitartrate
Normalized name: Cysteamine Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.
Study: NCT02961283
Drug: ASN003 MTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
Study: NCT04201275
Drug: HEC74647PA capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule administered orally once daily
Study: NCT04201275
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC74647PA capsule matching placebo administered orally once daily
Study: NCT03868202
Drug: Estradiol Transdermal Product
Normalized name: estradiol Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone replacement therapy will be given to postmenopausal women for up to 1 month.
Study: NCT02436031
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg administered 2 hours before normal sleep time
Study: NCT02436031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching desipramine administered 2 hours before normal sleep time
Study: NCT02144285
Drug: LY3113593
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02144285
Drug: LY3113593
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02144285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02144285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01946256
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02098616
Drug: DCV/ASV/BMS-791325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
Study: NCT02098616
Drug: DCV/ASV/BMS-791325 + RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
Study: NCT04040634
Drug: Standard control of Systolic Blood Pressure (SBP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Study: NCT01458717
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* 4 weeks rest, re-evaluation for resectability~* operation~* start maintenance chemotherapy within 4\~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle
Study: NCT00955097
Drug: Definity®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definity® injections given both pre-ablation and post-ablation
Study: NCT00113191
Drug: Veronate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00264654
Drug: BRL29060A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01815294
Drug: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1 = Treatment A, Cycle 2 = Treatment B